Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 59.89M P/E - EPS this Y 13.80% Ern Qtrly Grth -
Income -22.46M Forward P/E -2.18 EPS next Y -7.10% 50D Avg Chg -16.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -19.00%
Dividend N/A Price/Book N/A EPS next 5Y - 52W High Chg -60.00%
Recommedations 1.50 Quick Ratio 0.30 Shares Outstanding 34.70M 52W Low Chg 104.00%
Insider Own 71.34% ROA -110.10% Shares Float 10.01M Beta 0.11
Inst Own 2.99% ROE - Shares Shorted/Prior 46.46K/175.10K Price 1.74
Gross Margin - Profit Margin - Avg. Volume 156,164 Target Price 8.00
Oper. Margin - Earnings Date May 11 Volume 81,447 Change 0.58%
About MiNK Therapeutics, Inc.

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. It's product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

MiNK Therapeutics, Inc. News
03/25/24 All You Need to Know About MiNK Therapeutics, Inc. (INKT) Rating Upgrade to Buy
03/22/24 MiNK Therapeutics, Inc. (NASDAQ:INKT) Q4 2023 Earnings Call Transcript
03/21/24 Q4 2023 Mink Therapeutics Inc Earnings Call
03/21/24 MiNK Reports Fourth Quarter and Year-End 2023 Results
03/07/24 MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report
03/06/24 MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024
02/14/24 First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK’s Allogeneic INKT Cell Therapy and Agenus’ Botensilimab and Balstilimab
02/06/24 MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications
01/30/24 MiNK’s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene
12/20/23 ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development
11/09/23 MiNK Therapeutics Inc (INKT) Reports Q3 2023 Results: Clinical Progress Amid Financial Challenges
11/09/23 MiNK Therapeutics Reports Third Quarter 2023 Results
11/03/23 MiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023
11/03/23 MiNK Therapeutics Insider Ups Holding During Year
10/30/23 MiNK to Provide Third Quarter 2023 Financial Report and Corporate Update
09/27/23 MiNK Therapeutics To Present Data Update From Allogeneic iNKT Cells in Solid Tumors at SITC 2023
09/23/23 Can MiNK Therapeutics (NASDAQ:INKT) Afford To Invest In Growth?
08/24/23 MiNK Therapeutics to Participate in September Investor Conferences
08/10/23 MiNK Therapeutics Reports Second Quarter 2023 Results
07:30 AM MiNK to Provide Second Quarter 2023 Financial Report and Corporate Update
INKT Chatroom

User Image Biotechguy21 Posted - 2 days ago

$AGEN $INKT same game plan by these pos companies 🀑🀑🀑

User Image 2_logs_higher Posted - 2 days ago

$AGEN + $INKT All You Need to Know About MiNK Therapeutics, Inc. (INKT) Rating Upgrade to Buy https://finance.yahoo.com/news/know-mink-therapeutics-inc-inkt-160010067.html

User Image 2_logs_higher Posted - 1 week ago

$AGEN + $INKT https://finance.yahoo.com/news/mink-reports-fourth-quarter-end-110000135.html

User Image DonCorleone77 Posted - 1 week ago

$INKT MiNK Therapeutics reports Q4 EPS (16c), consensus (15c) "In 2023, MiNK made significant strides in advancing our allogeneic iNKT cell programs, contributing to a growing body of clinical data that underscores the unique advantages of iNKTs and their pivotal role in immunity," said Dr. Jennifer Buell, Chief Executive Officer and President at MiNK. "We expanded the scope of our pipeline, solidifying key partnerships such as our research agreement with ImmunoScape. As we move forward, our primary focus remains on advancing our lead program, agenT-797, particularly in indications where we have observed promising proof-of-concept data. We are pleased to announce the progression of this program into a Phase 2 study in gastroesophageal cancers and we anticipate sharing initial trial data later this year."

User Image Stock_Titan Posted - 1 week ago

$INKT MiNK Reports Fourth Quarter and Year-End 2023 Results https://www.stocktitan.net/news/INKT/mi-nk-reports-fourth-quarter-and-year-end-2023-0w7j91i3cm0l.html

User Image ChiefOG Posted - 1 week ago

$INKT πŸ‘€

User Image Jtlo Posted - 1 week ago

$AGEN buy when it’s lower. Garo has destroyed all his companies Just look how pathetic they are $agen $inkt $PTIX

User Image Stock_Titan Posted - 3 weeks ago

$INKT MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report https://www.stocktitan.net/news/INKT/mi-nk-to-provide-corporate-update-and-fourth-quarter-full-year-2023-8qvgok5bjiry.html

User Image Stock_Titan Posted - 3 weeks ago

$INKT MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024 https://www.stocktitan.net/news/INKT/mi-nk-announces-preclinical-data-showcasing-activity-of-mi-nk-215-0qcnexl4iw9q.html

User Image rag2riches Posted - 3 weeks ago

$INKT mink-215 poster at aacr

User Image rag2riches Posted - 3 weeks ago

$INKT ugh. They got a notice of deleting yesterday. They need to get their marketcap above 35 million for 10 days straight

User Image jacobsright Posted - 3 weeks ago

$INKT whens the reverse split ?

User Image 2_logs_higher Posted - 3 weeks ago

$AGEN $INKT

User Image Biotechguy21 Posted - 02/29/24

$AGEN $INKT $PTIX see a theme here? All are pos stocks and who is part of this? πŸ‘€πŸ‘€πŸ˜‚πŸ˜‚ RS mania

User Image Biotechguy21 Posted - 1 month ago

$INKT this pos is done for. Just like $AGEN and $PTIX πŸ‘‡πŸ‘‡πŸ˜‚πŸ˜‚

User Image rag2riches Posted - 1 month ago

$INKT this needs to stay above 1 to remain compliant. They also need to produce some very compelling preclinical data and make partnerships.

User Image Biotechguy21 Posted - 1 month ago

$AGEN $PTIX $INKT all pos stocks. can anyone defend these CEOs and Boards? πŸ€‘πŸ€‘πŸ˜‚πŸ˜‚πŸ‘€πŸ‘€

User Image Jtlo Posted - 1 month ago

$AGEN they know once the 20-1 is approved it’s going to be shorted to oblivion - wait until 7-8 to load up long You think they do a RS then dilute? Garo is so funny $ptix on a second RS within 2 years !!! Years within 2year $inkt on its way to its first Agen its second and a nasty 20-1 that rapes all retails and institutions that bought in between 2-4 What did they use to say? Anything under 2.40 is a steal Now you can grab the science of all three of his companies under a dollar

User Image Jtlo Posted - 1 month ago

$AGEN $INKT $PTIX remember

User Image Jtlo Posted - 1 month ago

$AGEN you can’t make this shit up- what did we say - garo fleeces investors - most importantly retail investors - look at what they did to $ptix which is on the cusp of a second RS - $inkt on its way for its first - garo is a pos and only cares about aligning his pockets while tormenting and destroying naive investors - real people that endure real life consequences.

User Image ArmanShorov4 Posted - 1 month ago

$AGEN why red, $INKT greed

User Image Biotechguy21 Posted - 1 month ago

$AGEN $INKT $PTIX pos stocks. are you seeing a theme? πŸ‘€πŸ‘€πŸ‘€πŸ‘€

User Image Jtlo Posted - 1 month ago

$AGEN $INKT $PTIX just saying

User Image Jtlo Posted - 1 month ago

$AGEN sleep well tonight - tomorrow will be a different day. Remember, your ceo is still garo - look at they did to poor $ptix $ $inkt Good luck

User Image rag2riches Posted - 1 month ago

$INKT finally real progress.

User Image Stock_Titan Posted - 1 month ago

$INKT First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK’s Allogeneic INKT Cell Therapy and Agenus’ Botensilimab and Balstilimab https://www.stocktitan.net/news/INKT/first-refractory-gastric-cancer-patient-dosed-in-phase-2-trial-with-gxnryrtnczd2.html

User Image Flowjob Posted - 1 month ago

$INKT PR team is rising from the dead but this fluffy news is not gonna relieve the bag holders here lol No real catalysts, Offering next super low on cash GL

User Image Stock_Titan Posted - 1 month ago

$INKT MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications https://www.stocktitan.net/news/INKT/mi-nk-therapeutics-agen-t-797-shows-promising-results-in-the-scy3pjnqbcnq.html

User Image Biotechguy21 Posted - 1 month ago

$INKT $AGEN $PTIX look closely and you will have your answer as to why these three are pos stocks πŸ‘€πŸ‘€πŸ‘€πŸ˜‚πŸ˜‚πŸ˜‚

User Image Jtlo Posted - 1 month ago

$AGEN believe in garo you believed in 30 years of nothing. Same fate will happen to his other companies. $ptix on the cusp of a second RS while $inkt heading for its first - might as well say agen will head to their second as well 1/2 billion share outstanding + science + garo selling at 6.50 = .60 a share

Analyst Ratings
HC Wainwright & Co. Buy Mar 21, 24
HC Wainwright & Co. Buy Aug 10, 23
HC Wainwright & Co. Buy May 12, 23
HC Wainwright & Co. Buy Apr 19, 23
Evercore ISI Group Outperform Mar 22, 23
HC Wainwright & Co. Buy Mar 22, 23
HC Wainwright & Co. Buy Aug 10, 22
B. Riley Securities Buy Jan 24, 22
William Blair Outperform Nov 9, 21
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
AGENUS INC Director Director Oct 12 Buy 1.1 22,975 25,273 21,772,863 10/16/23
AGENUS INC Director Director Aug 29 Buy 1.5168 29,678 45,016 21,734,887 08/31/23
AGENUS INC 10% Owner 10% Owner Aug 24 Buy 1.5 183,052 274,578 21,705,209 08/28/23
AGENUS INC Director Director May 10 Buy 1.47 45,426 66,776 21,640,473 05/12/23
ARMEN GARO H Director Director May 05 Sell 0.9485 100,000 94,850 1,866,400 05/05/23
AGENUS INC Director Director May 03 Buy 1.12 250,362 280,405 21,595,047 05/05/23
ARMEN GARO H Director Director May 02 Buy 0.9485 100,000 94,850 1,978,010 05/04/23
WIINBERG ULF Director Director Jul 18 Buy 1.36 20,000 27,200 298,300 07/21/22
AGENUS INC 10% Owner 10% Owner Oct 19 Buy 12 1,400,000 16,800,000 20,881,000 10/20/21